



# IDAHO DIVISION OF OCCUPATIONAL AND PROFESSIONAL LICENSES

*newsletter to promote pharmacy and drug law compliance*

## **The Sue Chew Award and Endowment**



Idaho State Representative Sue Chew passed away on April 17, 2024. Representative Chew worked as a pharmacist in Idaho; she later taught at Boise State University, and, in 2006, she was elected to the Idaho House of Representatives. Her 18 years as a state representative was the longest tenure of a Democrat in the history of the Idaho State Legislature.

The Idaho State University L.S. Skaggs College of Pharmacy, in partnership with the Idaho Board of Pharmacy, the Idaho Society of Health-System Pharmacy, and the Idaho State Pharmacy Association, established an award in the name of former Idaho State Representative Sue Chew. Representative Chew was presented with the award on March 28, 2024, during the Board of Pharmacy meeting.

An endowment has been created in hopes of continuing to celebrate, identify, and award



those who exemplify advocacy and community and, like Sue Chew, promote policy that enables improved health care to the people of Idaho.

If you would like to donate to the endowment, please follow this [link](#).

### ***New Idaho Practitioner Sales Reporting System Begins August 1, 2024***

This communication informs Idaho licensed/registered drug distributors – manufacturers, wholesale distributors (including virtual), and Idaho pharmacies – about a new process for monthly drug distribution reporting of prescription drug sales, including controlled substances (CS), to Idaho practitioners in accordance with the Rules of the Idaho State Board of Pharmacy ([IDAPA.24.36.01.501.03](#)).

The Idaho Division of Occupational and Professional Licenses (DOPL) is launching an **Idaho Practitioner Sales Reporting System** effective August 1, 2024.

According to the Idaho Board of Pharmacy administrative rules, an authorized drug distributor must submit drug distribution data monthly in a format specified by the Division.

Registration information is located at <https://pmpclearinghouse.net/opiatereporting>.

If you need additional help with registering, contact Bamboo Health at 844/966-4767; technical assistance is available Monday through Friday from 8 AM – 5 PM CT.

To satisfy reporting requirements, submit information by either:

- **Zero Report**

Zero sales to practitioners require a report in ARCOS format by the first of the following month.\*

- **Transaction Report**

All sales to practitioners require a report in ARCOS format by the first of the following month.\*

#### **Additional Information**

Idaho-licensed/registered drug distributors who sell prescription drugs shipped through a third-party logistics provider (3PL) are considered the product owners and are responsible for reporting sales, not the 3PL.

**\*Data Submission Guidelines will follow soon.**

***National Pharmacy Compliance News***  
A Service of the National Association of Boards  
of Pharmacy Foundation (NABPF)

Visit NABP's website for the latest regulatory updates and news from FDA, USP, NABP, and more.

**[Read National News](#)**

For more information on Monthly Prescriber Sales Reporting Requirements, please click on the Prescription Drug Monitoring Program (PDMP) banner in the Additional Board Information section at <https://dopl.idaho.gov/bop/>. Email questions to [PDMP@dopl.idaho.gov](mailto:PDMP@dopl.idaho.gov).

### ***\$350,000 Grant Awarded to the Idaho DOPL***

The Idaho Behavioral Health Council, through the state-directed opioid settlement fund, has awarded Idaho DOPL a \$350,000 grant to increase the accessibility of treatment for patients with opioid use disorder. DOPL will be using this funding to incentivize new nonphysician health care providers (eg, pharmacists, prescribing psychologists, physician assistants, advanced practice registered nurses) across Idaho to acquire Drug Enforcement Administration (DEA) registration and complete the education required for prescribing medications for opioid use disorder (MOUD). What is the incentive? The funds will be used to reimburse providers for the cost of DEA registration.

The cost of DEA registration is \$888. The \$350,000 grant will allow for 394 participant awards. This project will last three years. To qualify for the grant, the nonphysician prescriber must be licensed in Idaho, have practiced for two years or more, be a first-time applicant for DEA registration, and reside in Idaho. The applicant must have the appropriate education and training to prescribe MOUD. Preferences will be given to providers who demonstrate a genuine desire to implement MOUD prescribing and management and serve in a rural or underserved area without significant MOUD access. This grant is intended to engage new classes of health care providers who are covered under the federal Mainstreaming Addiction Treatment Act but could not otherwise previously prescribe MOUD.

Applications will be available on the Board [website](#) on July 1, 2024, under Resources/Forms. A committee will review applications, and applicants will be notified via email whether they have been selected to receive grant funds. Applications will be accepted beginning July 1, 2024, and will continue until funds have been exhausted or by June 30, 2025. DEA registration fees incurred before July 1, 2024, are not eligible for reimbursement under this grant and will not be considered.

To receive reimbursement, applicants must register with DEA and complete all required training for MOUD. Applicants can find the information for the process on the [DEA registration page](#) and the DEA Medication Assisted Treatment [informational page](#), as well as information for continuing education (CE) for the [Medication Access and Training Expansion Act \(MATE Act\)](#). An Idaho Practitioner CS Registration is required to obtain DEA registration. See the Board's website for more information.

The award amount of \$888 covers the cost of the DEA registration fee. Reimbursement will not be considered for any costs of CE or training required to obtain DEA registration. Many free education options comply with the MATE Act. If at any time the grant recipient is unable to maintain DEA registration, they must inform DOPL.

Recipients must agree to complete a total of three annual surveys to provide information on their experience prescribing MOUD in their practice. An email containing a link to access the survey will be emailed to grantees from DOPL every year for three years, beginning one year after obtaining DEA registration. Failure to participate in the survey may result in the requirement of repayment of funds.

Questions about this grant should be directed to DOPL and submitted via email to [Angela.Higgins@dopl.idaho.gov](mailto:Angela.Higgins@dopl.idaho.gov).

## **Delegate Management**

### **CS Registrants – PDMP Delegate List Review**

#### ***Is your delegate list up to date?***

The new year is an opportunity to ensure that the delegates assigned by you are still active and accurate. The delegate review is to ensure that delegate users of the Idaho PDMP are still authorized to perform searches on their supervisor's behalf. As a supervisor, you are responsible for activities performed within the system by your delegate(s). Please take a moment to perform the delegate review by doing the following.

From the Dashboard of your PDMP account (PMP AWAxE), click on the dropdown next to Menu at the top of the screen. Under User Profile, click on Delegate Management.

If a supervisor needs to remove a delegate connection from their account, they can do so from the Delegate Management Dashboard:

- Click "Remove." The delegate is removed but is kept in pending status.

If a supervisor wants to re-add a previous delegate who is in pending status:

- Select pending delegate from the list on your Delegate Management Dashboard.
- Click "Approve."

If a supervisor would like to completely remove a delegate:

- Select the pending delegate.
- Click "Reject" – the delegate will be completely removed from the account.

For more detailed information, click on <https://pmpawarxe.zendesk.com/hc/en-us/articles/27383265489427-Approving-Removing-Delegates>.

## **Shortages: Help Public Health Help You**

### ***By Lori Peck, Public Health Preparedness Planner***

During critical medication and other supply shortages, local public health preparedness (PHP) teams can support our health care partners with locating and distributing scarce resources,

including through the Strategic National Stockpile when necessary. To prepare for urgent situations, inventory information request procedures are tested once per quarter.

Previously, only some pharmacies (primarily community) were included in this process. However, hospitals and other health care facilities that administer and/or dispense medication directly to patients are also affected by shortages. To support PHP partners and communities more effectively, PHP teams would like to include all licensed entities in the inventory information request process.

PHP teams have heard from partners that the current inventory information request process has been inconvenient and cumbersome. As an alternative, PHP teams have developed a short online survey in which a pharmacy would simply indicate the quantity of the listed item on hand, typically a specific strength (eg, number of 100 mg tablets) or formula (eg, liquid suspension). Quarterly test surveys would only have one inventory question, but, during shortages, there may be multiple inventory questions on the same survey. In both cases, answers would not be visible to other providers, only the PHP team.



Our PHP team would love to hear your feedback on this proposed solution and any other suggestions for how we can better support our partners (via this [link](#) or the QR code). If you would like further information, let PHP know in the survey and we will reach out. As always, feel free to contact your local PHP team (contact information for each district is linked on the survey completion page). Thank you!

### ***Changes Pharmacists May Make to Schedule II Prescription Drug Orders***

DEA is in the process of creating new regulations related to changes a pharmacist may make to Schedule II prescriptions. For now, the agency has a guidance document that indicates, until new regulations have been drafted, “pharmacists should adhere to state regulations or policy regarding those changes that a pharmacist may make to a Schedule II prescription after oral consultation with the prescriber.”<sup>1</sup>

Firstly, what is required on a prescription for Schedule II substances? Schedule II CS prescriptions may be written or electronic (in certain emergency situations, an oral prescription may be permissible).<sup>2</sup> If written, the paper prescription must be written in ink or indelible pencil, typewritten, or printed on a computer printer and must be manually signed by the practitioner on the date when issued.<sup>2</sup> Prescription blanks shall utilize non-copyable paper that contains security provisions against copying, which results in some indication on the copy that it is a copy and, therefore, renders it null and void (Uniform Controlled Substance Act).

A prescription is valid if it is issued by a prescriber for a legitimate medical purpose arising from a prescriber-patient relationship that includes a documented patient evaluation adequate to

establish diagnoses, if applicable, and identify underlying conditions and/or contraindications to the treatment. A prescription for CS is invalid if written for the prescriber or their immediate family.<sup>2</sup> This includes cases of an advanced practice registered nurse, self, spouse, children (biological, foster, adopted), parent, sibling, grandparent, grandchild, or the same relation by marriage (IDAPA 24.34.01).

Prescriptions must: be dated and signed on the date when issued, include the patient's full name and address, include the practitioner's full name, address, and DEA registration, include the drug name, the drug strength, the dosage form, the quantity prescribed, and the directions for use.<sup>2</sup> Refills for Schedule II CS are prohibited.<sup>2</sup> However, a practitioner may issue multiple prescriptions authorizing the patient to receive a total of up to a 90-day supply if certain conditions are met.<sup>2</sup> So, what changes may be made by a pharmacist, and, as importantly, what changes cannot be made by a pharmacist?

#### **Elements a Pharmacist May Never Add:**

- Patient's Name;
- Drug Name;
- Prescriber's Name; and
- Prescriber's Signature.

#### **\*Elements a Pharmacist May Change:**

- Patient's Full Name (corrected, not added);
- Patient's Address; and
- Prescriber's DEA Registration Number.

\*This information, however, must be verified through a reliable source.

If you are ever unsure of an Idaho pharmacist's scope of practice, review the [Idaho Pharmacy Act](#) and the [Rules of the Idaho State Board of Pharmacy](#).

#### References:

1. *Changes Pharmacists May Make to Schedule II Paper Prescriptions, Guidance Document*. Drug Enforcement Administration, Diversion Control Division. Published October 18, 2022. [https://deادiversion.usdoj.gov/GDP/\(DEA-DC-063\)\(EO-DEA257\)\\_Changes\\_to\\_a\\_Prescription\\_Guidance\\_-\\_Final.pdf](https://deادiversion.usdoj.gov/GDP/(DEA-DC-063)(EO-DEA257)_Changes_to_a_Prescription_Guidance_-_Final.pdf)
2. *Pharmacist's Manual: An Informational Outline of the Controlled Substances Act*. Drug Enforcement Administration, Diversion Control Division. 2022. [https://deادiversion.usdoj.gov/GDP/\(DEA-DC-046R1\)\(EO-DEA154R1\)\\_Pharmacist's\\_Manual\\_DEA.pdf](https://deادiversion.usdoj.gov/GDP/(DEA-DC-046R1)(EO-DEA154R1)_Pharmacist's_Manual_DEA.pdf)



## 2024 Board Meeting Schedule

The Board will meet quarterly on the following dates:

- June 13\*
- September 26
- December 19

\*On June 13, proposed zero-based regulation changes to the Rules of the Idaho State Board of Pharmacy will be reviewed. There will be time for public comment. Feel free to attend in person or online. The draft rule chapter under review can be found [here](#). Rules related to compounding, sterile preparation, hazardous drugs, and radiopharmaceuticals are under consideration for revision, as is the requirement for CE and more. Licensee and registrant feedback is welcomed!

All meetings start at 8:30 AM and are held at the Division of Occupational and Professional Licenses, 11341 W Chinden Blvd, Boise, ID 83714. Meetings may also be attended virtually. See meeting agenda for the link to attend virtually at <https://dopl.idaho.gov/calendar>.

An additional negotiated rulemaking hearing will be held on August 21, 2024. Check the calendar on the Board's website for times. Written public comments can be submitted to [support.hp@dopl.idaho.gov](mailto:support.hp@dopl.idaho.gov).

**Health Professions Recovery Program**  
Division of Occupational and Professional Licenses  
(208) 577-2489

Licensure Preservation

Support

Recovery

Confidential

Dependency

Unemployment

Unsafe Practice

Shame

The Health Professions Recovery Program offers professionals the opportunity to maintain licensure, return to safe and competent practice, maintain good personal health, and avoid the personal and professional risks associated with mental health and substance

## Health Professional Recovery Program

Are you working long hours and feeling burned out?

Do you feel yourself going down the wrong path?

Are you ready to make changes?

You can choose the direction you are going and get help with substance use or mental health.

Idaho DOPL offers a confidential, nonpunitive program. This program was created to assist medical professionals (doctors, nurses, dentists, pharmacists, etc) who have or are at risk of developing an addiction. The program's purpose is to assist professionals and their families to identify substance use disorders that pose a potential threat to their careers and get them the help they need.

If you answered yes to any of the questions above, let us help you preserve your license and get you on the road to recovery. For further information about this program, contact Katie Stuart.

Program Manager: Katie Stuart, CIP

Phone: 208/577-2489

Email: [Katie.Stuart@dopl.idaho.gov](mailto:Katie.Stuart@dopl.idaho.gov)

Website: [Welcome to Division of Occupational and Professional Licenses \(idaho.gov\)](http://Welcome to Division of Occupational and Professional Licenses (idaho.gov))

---

*The Idaho Board of Pharmacy News is published by the Idaho Board of Pharmacy and the National Association of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.*

*Nicki Chopski, PharmD, ANP - State News Editor*

*Lemrey "Al" Carter, PharmD, MS, RPh - National News Editor & Executive Editor*

*Megan Pellegrini - Publications and Editorial Manager*

---

**11341 W Chinden Blvd, Building #4 | Boise, ID 83714**

---